These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 8389705)
1. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae. Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705 [TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615 [TBL] [Abstract][Full Text] [Related]
3. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Aronoff SC; Jacobs MR; Johenning S; Yamabe S Antimicrob Agents Chemother; 1984 Oct; 26(4):580-2. PubMed ID: 6097169 [TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam. Sader HS; Tosin I; Sejas L; Miranda E Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842 [TBL] [Abstract][Full Text] [Related]
5. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Higgins PG; Wisplinghoff H; Stefanik D; Seifert H Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of YTR 830. Jacobs MR; Aronoff SC; Appelbaum PC; Yamabe S J Chemother; 1989 Jun; 1(3):151-4. PubMed ID: 2552029 [TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases. Gatermann S; Marre R Infection; 1991; 19(2):106-9. PubMed ID: 1646771 [TBL] [Abstract][Full Text] [Related]
8. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. Nomura S; Hanaki H; Nagayama A J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ampicillin alone and in combination with different concentrations of 6 beta-bromopenicillanic acid, clavulanic acid and mecillinam. Stobberingh EE; Houben AW; van Boven CP Scand J Infect Dis; 1987; 19(1):105-12. PubMed ID: 3031812 [TBL] [Abstract][Full Text] [Related]
10. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017 [TBL] [Abstract][Full Text] [Related]
11. [In vitro comparison of the beta lactamase-inhibitory action of clavulanic acid and sulbactam in ampicillin-resistant enterobacteria]. Grimm H Arzneimittelforschung; 1987 Oct; 37(10):1116-9. PubMed ID: 3501722 [TBL] [Abstract][Full Text] [Related]
12. Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis. Sorg TB; Cynamon MH J Antimicrob Chemother; 1987 Jan; 19(1):59-64. PubMed ID: 3030999 [TBL] [Abstract][Full Text] [Related]
13. Synergy of clavulanic acid, sulbactam and tazobactam (YTR 830) with amoxycillin against fifty beta-lactamase-producing strains of Haemophilus influenzae. Simonet M; Moittie D; Philippon A; Descamps P; Veron M J Antimicrob Chemother; 1989 May; 23(5):798-800. PubMed ID: 2547748 [No Abstract] [Full Text] [Related]
14. [Sulbactam and clavulanic acid: studies of enzyme kinetics and synergism with ampicillin and mezlocillin]. Cullmann W; Binder S; Stieglitz M Immun Infekt; 1987 May; 15(3):103-9. PubMed ID: 3038733 [TBL] [Abstract][Full Text] [Related]
15. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam. Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864 [TBL] [Abstract][Full Text] [Related]
16. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors. Moosdeen F; Keeble J; Williams JD Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004 [TBL] [Abstract][Full Text] [Related]
17. Beta-lactamase inhibitors and Acinetobacter spp. Eng RH; Smith SM; Cherubin CE J Antimicrob Chemother; 1990 Sep; 26(3):449-51. PubMed ID: 2172200 [No Abstract] [Full Text] [Related]
18. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin. Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820 [TBL] [Abstract][Full Text] [Related]
19. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Appelbaum PC; Jacobs MR; Spangler SK; Yamabe S Antimicrob Agents Chemother; 1986 Nov; 30(5):789-91. PubMed ID: 3026241 [TBL] [Abstract][Full Text] [Related]